u/laila_almeida
Contributes reviews on supplier material. Based in Kumasi.
member · joined 14 May 2025
Overview — page 2 of 5
comment on small win: TRIUMPH stopped being a problem at week 15 in c/trialwatch · 47 points · 1 months ago
I am going to push back on this slightly.
comment on [Question] Sweden — has anyone got a straight answer on order records in c/vendorvetting · 10 points · 1 months ago
Is that a VendorInvestigate result or are you quoting the vendor COA?
comment on genuine question about incretin that I am slightly embarrassed to ask in c/glp1science · 102 points · 2 months ago
Not convinced. The evidence does not support that reading.
comment on [Discussion] can we stop arguing about research peptides until somebody posts a number in c/researchpeptides · 34 points · 2 months ago
evidence-level statements required: in vitro, rodent, or human
comment on help me understand long term, I have read the wiki twice in c/maintenancephase · 1 points · 2 months ago
This is correct. Weight variance is normal at maintenance.
comment on 18 months in and TRIUMPH is still the thing I get wrong in c/trialwatch · -31 points · 2 months ago
Strongly agree. Phase 2 is investigational, not conclusive.
comment on [Discussion] dose stretching is doing more work than we give it credit for in c/maintenancephase · 175 points · 2 months ago
Regain on a taper is expected. 20% back over 26 weeks, which matches the discontinuation data. Planned for it.
comment on crypto — my 18-week log, condensed into one table in c/cryptopay · 4 points · 3 months ago
Strongly agree. Escrow is non-negotiable for groups.
comment on [Vendor] QST order #2 — Canada, 17 days, no drama, receipts inside in c/researchpeptides · 18 points · 3 months ago
Not to be pedantic but secretagogue and thymosin are being used interchangeably and they are not interchangeable in real life.
comment on help me understand regain, I have read the wiki twice in c/maintenancephase · 1 points · 3 months ago
Edit to your parent would help — the concentration you quoted assumes one scenario and you have written another above it.
comment on someone explain identity to me like I have not read a paper in years in c/researchpeptides · 148 points · 3 months ago
The confident tone is doing a lot of work that the evidence is not.
comment on three years of confirmations threads, summarised so you do not have to read them in c/cryptopay · 57 points · 3 months ago
network selection matters, wrong chain is the expensive typo
comment on three years of confirmations threads, summarised so you do not have to read them in c/cryptopay · 67 points · 3 months ago
Did you check confirmation speed on that chain?
comment on [Results] 62 weeks, 45kg, and FLOW was the hard part in c/trialwatch · 22 points · 4 months ago
phase 2 is not phase 3, smaller n and shorter trial
comment on [Lab] 11th independent test on QSC, and the trend is the interesting part in c/trialwatch · 69 points · 4 months ago
Disagree but this is the good kind of wrong — it is specific enough to be checked.
comment on 5 months in and Medutest is still the thing I get wrong in c/vendorvetting · 44 points · 5 months ago
You have restated the marketing copy. What is the actual substance here.
comment on [Discussion] we are measuring vendor at the wrong time and calling it noise in c/vendorvetting · 25 points · 5 months ago
Yeah, GL Biochem took 8 days and the material was flawless. Both of those things are true.
comment on the SURPASS question that gets asked weekly, answered properly in c/trialwatch · 76 points · 5 months ago
SURMOUNT-4 discontinuation arm showed regain. That is the reality of a chronic disease treatment, not a failure.
comment on the SURPASS question that gets asked weekly, answered properly in c/trialwatch · 1 points · 5 months ago
dropout handling matters, especially on GI-heavy populations
comment on am I the only one who found testing harder than the injections in c/vendorvetting · 349 points · 6 months ago
The confident tone is doing a lot of work that the evidence is not.